Y-Intercept (HK)
CGEM icon

Y-Intercept (HK)’s Cullinan Oncology CGEM Stock Holding History

Y-Intercept (HK)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-80,648
Closed -$1.47M – 1635
2026
Q2 		$1.47M Sell
80,648
-14,769
-15% -$219K 0.03% 867
2026
Q1 		$1.36M Buy
+95,417
New +$1.23M 0.03% 906
2025
Q3 		– Sell
-11,129
Closed -$83.8K – 1610
2025
Q2 		$83.8K Buy
+11,129
New +$89.4K ﹤0.01% 1545
2024
Q4 		– Sell
-25,369
Closed -$425K – 1244
2024
Q3 		$425K Buy
25,369
+7,343
+41% +$130K 0.03% 851
2024
Q2 		$314K Buy
+18,026
New +$384K 0.02% 1022

Other funds holding CGEM

Ellsworth Advisors
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Bangor Savings Bank
Bangor Savings Bank Bangor, Maine $1.31B AUM 12.25% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s CGEM Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Cullinan Oncology (CGEM) in Q3 2026, closing a stake of 80,648 shares — an estimated $1.47M sold.

Y-Intercept (HK) first reported a position in CGEM in Q2 2024 and held it in 5 quarters. The position peaked at $1.47M in Q2 2026. 15 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Cullinan Oncology position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 80,648 Cullinan Oncology shares in Q3 2026, an estimated $1.47M.
  • Y-Intercept (HK) first reported a position in Cullinan Oncology in Q2 2024 and held it in 5 quarters.
  • Y-Intercept (HK)'s Cullinan Oncology position peaked at $1.47M in Q2 2026.
  • 15 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.